The Death of Addiction: How One Dose of Magic Mushrooms is Killing Cocaine Cravings (AMA Confirmed)

A peer-reviewed study recently published in the American Medical Association’s journal, JAMA Network Open, has provided clinical evidence regarding the efficacy of psilocybin in treating Cocaine Use Disorder (CUD). The findings indicate that a single, high-dose administration of the compound, when integrated with structured psychological support, may lead to a significant reduction in cocaine consumption and cravings.

Study Methodology and Design

The research utilized a randomized, double-blind clinical trial to evaluate the safety and therapeutic potential of psilocybin. The study focused on adults diagnosed with moderate-to-severe Cocaine Use Disorder, a condition for which there are currently no FDA-approved pharmacological treatments.

Participants were administered either a 25 mg dose of psilocybin or an active placebo within a controlled clinical environment. This pharmacological intervention was paired with a 12-week standardized therapy program designed to facilitate cognitive restructuring and behavioral change.

Pharmacological Mechanisms: Neuroplasticity and 5-HT2A Agonism

The primary mechanism explored in the study involves psilocybin’s role as an agonist for 5-HT2A serotonin receptors. Unlike traditional addiction treatments that focus on long-term chemical maintenance, psilocybin appears to induce a state of heightened neuroplasticity.

Physiologically, the compound disrupts the Default Mode Network (DMN)—the area of the brain associated with repetitive thought patterns and ingrained habits. By temporarily suspending these neural loops, the brain is hypothesized to "reset," allowing for the formation of new, non-addictive neural pathways. This allows for a break in the dopaminergic cycle that characterizes cocaine dependency.

Key Clinical Outcomes

The data collected during the 180-day follow-up period demonstrated several statistically significant results:

• Reduction in Use: The psilocybin group showed a marked increase in cocaine-free days compared to the control group.

• Safety Profile: Researchers reported no serious adverse events (SAEs), suggesting the compound is physiologically safe for administration in a supervised setting.

• Duration of Effect: The reduction in cravings was not temporary; participants showed sustained behavioral improvements six months after the single-dose intervention.

Implications for Addiction Medicine

The AMA-published findings suggest a paradigm shift in addiction medicine, moving toward episodic, plant-derived alkaloid treatments rather than chronic daily medication. As clinical trials move into later stages, the focus remains on the biological intersection of psychedelic compounds and the brain’s reward systems. This research contributes to a growing body of evidence regarding the medical utility of controlled entheogens in treating refractory substance use disorders. link to the study below: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848757